A detailed history of Fort Washington Investment Advisors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Fort Washington Investment Advisors Inc holds 2,561,543 shares of BMY stock, worth $102 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares
2,561,543
Previous 2,542,827 0.74%
Holding current value
$102 Million
Previous $138 Million 0.74%
% of portfolio
0.91%
Previous 0.9%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $897,993 - $1.02 Million
18,716 Added 0.74%
2,561,543 $139 Million
Q4 2023

Jan 17, 2024

BUY
$48.48 - $57.85 $26.3 Million - $31.4 Million
542,210 Added 27.1%
2,542,827 $130 Million
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $1.17 Million - $1.31 Million
-20,267 Reduced 1.0%
2,000,617 $116 Million
Q2 2023

Jul 28, 2023

SELL
$63.71 - $70.74 $1.32 Million - $1.46 Million
-20,689 Reduced 1.01%
2,020,884 $129 Million
Q1 2023

Apr 28, 2023

SELL
$65.71 - $74.53 $1.1 Million - $1.25 Million
-16,734 Reduced 0.81%
2,041,573 $142 Million
Q4 2022

Jan 30, 2023

SELL
$68.48 - $81.09 $31.5 Million - $37.3 Million
-459,652 Reduced 18.25%
2,058,307 $148 Million
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $57,244 - $33.8 Million
-440,343 Reduced 14.88%
2,517,959 $179 Million
Q2 2022

Aug 05, 2022

SELL
$72.62 - $79.98 $105 Million - $116 Million
-1,448,384 Reduced 32.87%
2,958,302 $228 Million
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $1.75 Million - $2.1 Million
-28,476 Reduced 0.64%
4,406,686 $322 Million
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $39 Million - $45.5 Million
727,119 Added 19.61%
4,435,162 $277 Million
Q3 2021

Nov 09, 2021

BUY
$59.17 - $69.31 $98.8 Million - $116 Million
1,669,049 Added 81.86%
3,708,043 $219 Million
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $2.5 Million - $2.72 Million
40,340 Added 2.02%
2,038,994 $136 Million
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $5.54 Million - $6.23 Million
93,392 Added 4.9%
1,998,654 $126 Million
Q4 2020

Feb 03, 2021

SELL
$57.74 - $65.43 $8.42 Million - $9.54 Million
-145,873 Reduced 7.11%
1,905,262 $118 Million
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $6.36 Million - $7.05 Million
110,797 Added 5.71%
2,051,135 $124 Million
Q2 2020

Jul 31, 2020

SELL
$54.82 - $64.09 $24,559 - $28,712
-448 Reduced 0.02%
1,940,338 $114 Million
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $1.61 Million - $2.33 Million
34,619 Added 1.82%
1,940,786 $108 Million
Q4 2019

Feb 03, 2020

SELL
$49.21 - $64.19 $14.6 Million - $19 Million
-295,834 Reduced 13.43%
1,906,167 $122 Million
Q3 2019

Nov 08, 2019

BUY
$42.77 - $50.71 $4.72 Million - $5.59 Million
110,301 Added 5.27%
2,202,001 $112 Million
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $5.75 Million - $6.36 Million
128,914 Added 6.57%
2,091,700 $94.9 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $6.61 Million - $7.88 Million
-146,550 Reduced 6.95%
1,962,786 $93.6 Million
Q4 2018

Feb 05, 2019

SELL
$48.76 - $63.23 $2.94 Million - $3.81 Million
-60,287 Reduced 2.78%
2,109,336 $110 Million
Q3 2018

Nov 07, 2018

SELL
$55.19 - $62.25 $13.3 Million - $15 Million
-240,677 Reduced 9.99%
2,169,623 $135 Million
Q2 2018

Jul 27, 2018

SELL
$50.53 - $62.98 $243,200 - $303,122
-4,813 Reduced 0.2%
2,410,300 $133 Million
Q1 2018

May 02, 2018

SELL
$59.92 - $68.98 $178,381 - $205,353
-2,977 Reduced 0.12%
2,415,113 $153 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $22.5 Million - $24.5 Million
375,561 Added 18.39%
2,418,090 $148 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $1.07 Million - $1.24 Million
19,424 Added 0.96%
2,042,529 $130 Million
Q2 2017

Aug 10, 2017

BUY
N/A
2,023,105
2,023,105 $113 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Fort Washington Investment Advisors Inc Portfolio

Follow Fort Washington Investment Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort Washington Investment Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Fort Washington Investment Advisors Inc with notifications on news.